Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > "Griproom" article - 10 signs your company is to be acquired

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Nov 19, 2022 3:26pm

208 Views

Post# 35112900

RE:RE:"Griproom" article - 10 signs your company is to be acquired

Capitalista .... those seeking to manipulate a stock look for ones that are thinly traded and then try to keep everyone else away from investing in the company, as Hcallahan44 and Bumbleberry have been trying to do here and others on different message boards.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing